-20webclip.png)
£4.7M
The financing round was led by SCVC with participation from a group of institutional investors and agencies.
"Essentially, our technology generates very small droplets which are ideal for peripheral inhalation drug delivery, and also the potential for systemic drug delivery through the inhalation route rather than via injection."
-20webclip.png)
